ReviewDiscover nano2026
Engineered exosomes for targeted glioma therapy: overcoming the blood-brain barrier with nature-inspired nanocarriers.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bridging the "Valley of Death" in Antifungal Therapy: Next-Generation Biomimetic and Exosome-Inspired Nanocarriers for Invasive Candidiasis.Journal of fungi (Basel, Switzerland) · 2026Review
- Mapping the landscape and evolution of drug delivery for glioma: a bibliometric and visual analysis.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas mainly glioblastoma multiforme (GBM) are the greatest lethal primary brain tumors, marked by rapid progression, high heterogeneity, and poor therapeutic outcomes. A main challenge in treating gliomas lies in the limited permeability of the blood-brain barrier (BBB), which restricts drug access to the tumor site. Conventional treatment protocols, including surgery, radiotherapy, and the Stupp regimen, offer only modest survival aids due to drug resistance and inefficient delivery. Recently, nanotechnology-based approaches have gained attention for enhancing drug transport across the BBB. Among them, exosomes endogenous extracellular vesicles have emerged as promising nanocarriers due to their innate biocompatibility, low immunogenicity, and natural ability to cross the BBB. These vesicles can be planned to deliver therapeutic agents selectively to tumor cells and modulate the tumor microenvironment (TME), influencing processes as well as angiogenesis, immune evasion, and intercellular signaling. This review articulates the innovative contributions of exosome-based drug delivery systems in glioma management, highlighting recent advancements in bioengineering approaches and their dual role in treatment and diagnostics (theranostics). By speaking the biological barriers to drug delivery and enhancing targeted therapeutic effects, exosomes represent a significant leap forward in precision medicine for glioma therapy. Additional clinical and translational research is crucial to fully realize the potential of exosomes as effective delivery systems in glioma treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.